To: info@selectxpharm.com

From: Edward Hammond https://www.nshine-project.org
Subject: IBC Minutes
Cc: "'Johnson, Michelle \(NIH/OD\) [C]'" <johnsom1@od.nih.gov>

Attachments:

Dear Ms. Griffin:

I have recieved your reply to my requet for minutes or, well, errr, my complaint to NIH. I requested minutes since March 2003. You have sent the minutes of one meeting, that of 13 September 2006. Please send the missing minutes covering the entire timeframe of my request.

Sincerely,

Edward Hammond



SelectX Pharmaceuticals, Inc.
One Innovation Drive
Worcester, MA 01605
ph 508-798-0216 / 1x 508-798-0217
info@selectxpharm.com
www.selectxpharm.com

Mr. Edward Hammond Director The Sunshine Project PO Box 41987 Austin TX 78704

March 9, 2007

Dear Mr. Hammond,

I am writing in response to your request for the minutes of the annual meeting of SelectX Pharmaceutical's Institutional Biosafety Committee. You will find a copy of the minutes enclosed.

Sincerely,

Munean deiffer Dr. Maureen A. Griffin

Staff Scientist

cc: Michelle Johnson-Lancaster, IBC Coordinator, Office of Biotechnology Activities, National Institutes of Health

Minutes from the Institutional Biosafety Committee meeting for SelectX Pharmaceuticals Meeting date: September 13, 2006

In attendance:

Maureen Griffin – Staff Scientist, SelectX, and IBC Chair Michael Chaparian – President, SelectX Branden Wolner – Staff Scientist, SelectX Max Lombardo – Consultant, Safety Partners, Inc. Dean Stamoulis – Community representative Michael Brady – Community representative

Meeting began late because Cheryl Catanzaro, a community rep, failed to show up. Michael Brady was called in as a last-minute back up.

Meeting began with a presentation by Mr. Lombardo outlining the purpose of the IBC. (Presentation attached to the minutes).

It was realized that, through an oversight, the IBC is lacking a member who is employed by SelectX but does not have a Ph.D. This error will be corrected in future, but as the recombinant DNA protocols were approved last year and have not changed, the meeting went forward as planned.

Mr. Chaparian presented a company overview and history (Presentation attached to the minutes).

Mr. Brady, the new community representative, was given a tour of the lab. Safety procedures and waste disposal program were explained.

Recombinant DNA protocols have not changed. Because Mr. Brady was called in at the last minute, he had not been provided with a copy of the protocols. It was agreed that Ms. Griffin will send Mr. Brady the protocols to review, and a vote to approve the protocols will be held via email.

Meeting adjourned

Signed by attendees:

Maureen A.S. Griffin

Michael G. Chaparian

Branden Wolner

Dean Stamoulis

Michael Brady

Massimo Lombardo

Minutes from the Institutional Biosafety Committee meeting for SelectX Pharmaceuticals Meeting date: September 13, 2006

In attendance:

Meeting adjourned

Maureen Griffin – Staff Scientist, SelectX, and IBC Chair Michael Chaparian – President, SelectX Branden Wolner – Staff Scientist, SelectX Max Lombardo – Consultant, Safety Partners, Inc. Dean Stamoulis – Community representative

Michael Brady – Community representative

Meeting began late because Cheryl Catanzaro, a community rep, failed to show up. Michael Brady was called in as a last-minute back up.

Meeting began with a presentation by Mr. Lombardo outlining the purpose of the IBC. (Presentation attached to the minutes).

It was realized that, through an oversight, the IBC is lacking a member who is employed by SelectX but does not have a Ph.D. This error will be corrected in future, but as the recombinant DNA protocols were approved last year and have not changed, the meeting went forward as planned.

Mr. Chaparian presented a company overview and history (Presentation attached to the minutes).

Mr. Brady, the new community representative, was given a tour of the lab. Safety procedures and waste disposal program were explained.

Recombinant DNA protocols have not changed. Because Mr. Brady was called in at the last minute, he had not been provided with a copy of the protocols. It was agreed that Ms. Griffin will send Mr. Brady the protocols to review, and a vote to approve the protocols will be held via email.

Signed by attendees:	Signature	Date
Maureen A.S. Griffin		
Michael G. Chaparian		
Branden Wolner		
Dean Stamoulis		
Michael Brady		
Massimo Lombardo	massing Sombrale	9/25/06

Minutes from the Institutional Biosafety Committee meeting for SelectX Pharmaceuticals Meeting date: September 13, 2006

In attendance:

Meeting adjourned

Maureen Griffin – Staff Scientist, SelectX, and IBC Chair Michael Chaparian – President, SelectX Branden Wolner – Staff Scientist, SelectX Max Lombardo – Consultant, Safety Partners, Inc. Dean Stamoulis – Community representative Michael Brady – Community representative

Meeting began late because Cheryl Catanzaro, a community rep, failed to show up. Michael Brady was called in as a last-minute back up.

Meeting began with a presentation by Mr. Lombardo outlining the purpose of the IBC. (Presentation attached to the minutes).

It was realized that, through an oversight, the IBC is lacking a member who is employed by SelectX but does not have a Ph.D. This error will be corrected in future, but as the recombinant DNA protocols were approved last year and have not changed, the meeting went forward as planned.

Mr. Chaparian presented a company overview and history (Presentation attached to the minutes).

Mr. Brady, the new community representative, was given a tour of the lab. Safety procedures and waste disposal program were explained.

Recombinant DNA protocols have not changed. Because Mr. Brady was called in at the last minute, he had not been provided with a copy of the protocols. It was agreed that Ms. Griffin will send Mr. Brady the protocols to review, and a vote to approve the protocols will be held via email.

Signed by attendees: Maureen A.S. Griffin Michael G. Chaparian Branden Wolner Dean Stamoulis Michael Brady Massimo Lombardo